HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA)

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Humacyte to a loss of $0.10 per share from $0.09, while maintaining a Buy rating and a $4.00 price target.
• Humacyte reported a quarterly loss of $0.16 per share, missing the $0.11 consensus estimate, while revenue of $0.41 million fell short of expectations of $1.04 million.
• Shares opened at $0.60, near their 52-week low of $0.53. Analyst sentiment remains mixed, with a Moderate Buy consensus but recent target-price cuts and a Strong Sell downgrade from Wall Street Zen.

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Research analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for Humacyte in a research note issued on Thursday, August 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.10) for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Humacyte's current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Humacyte's Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at ($0.07) EPS, FY2029 earnings at $0.09 EPS and FY2030 earnings at $0.31 EPS.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). The business had revenue of $0.41 million during the quarter, compared to analysts' expectations of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%.

HUMA has been the subject of a number of other reports. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. TD Cowen dropped their target price on shares of Humacyte from $1.50 to $1.25 and set a "buy" rating on the stock in a research report on Wednesday, June 17th. Wall Street Zen cut shares of Humacyte from a "sell" rating to a "strong sell" rating in a research note on Saturday. Benchmark cut their target price on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research note on Thursday. Finally, BTIG Research restated a "buy" rating and set a $2.00 price target on shares of Humacyte in a research report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $6.11.

Humacyte Price Performance

Humacyte stock opened at $0.60 on Monday. The company's fifty day moving average price is $0.78 and its 200 day moving average price is $0.90. Humacyte has a 1 year low of $0.53 and a 1 year high of $2.55. The stock has a market capitalization of $163.08 million, a P/E ratio of -1.23 and a beta of 2.54. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21.

Insider Buying and Selling

In other news, Director Kathleen Sebelius acquired 56,818 shares of Humacyte stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average cost of $0.88 per share, with a total value of $49,999.84. Following the purchase, the director owned 148,025 shares in the company, valued at $130,262. This trade represents a 62.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.10% of the company's stock.

Institutional Investors Weigh In On Humacyte

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Humacyte by 7.4% during the third quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company's stock worth $13,085,000 after acquiring an additional 520,431 shares during the last quarter. BlackRock Inc. acquired a new stake in Humacyte in the 2nd quarter valued at about $3,777,000. Geode Capital Management LLC lifted its stake in Humacyte by 20.2% in the 4th quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company's stock worth $3,574,000 after purchasing an additional 624,220 shares in the last quarter. UBS Group AG lifted its stake in Humacyte by 48.8% in the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company's stock worth $2,862,000 after purchasing an additional 976,275 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Humacyte by 17.8% during the 4th quarter. State Street Corp now owns 2,837,276 shares of the company's stock worth $2,725,000 after purchasing an additional 429,233 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte News Summary

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $4.00 price target, substantially above Humacyte’s recent trading level. The firm still projects a transition to positive earnings in FY2029 and FY2030, at $0.09 and $0.31 per share, respectively.
• Neutral Sentiment: Humacyte’s shares remain near their 52-week low, while trading volume has been significantly above average. That combination highlights elevated investor interest but also substantial volatility and uncertainty around the company’s outlook.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $0.46 from $0.37 and cut its FY2027 estimate to a loss of $0.30 from $0.26. It also lowered quarterly estimates for Q3 and Q4 2026 and Q3 and Q4 2027, indicating expectations for wider near-term losses.
• Negative Sentiment: The analyst lowered longer-term estimates as well, cutting FY2029 EPS to $0.09 from $0.20 and FY2030 EPS to $0.31 from $0.50. Although profitability is still projected, the reduced forecasts weaken the valuation case and may pressure the stock. Benchmark Issues Pessimistic Forecast for Humacyte Stock Price
• Negative Sentiment: Wall Street Zen downgraded Humacyte to Strong Sell, adding to the negative sentiment surrounding the stock. Humacyte Lowered to Strong Sell Rating by Wall Street Zen

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source